Moonlight AI has successfully raised $3.3 million in seed funding to enhance its AI-driven diagnostic software for hematology and oncology laboratories. The investment was co-led by Lotus One Investment, VP Venture Partners, and MEDIN Fund, along with participation from N&V Capital and existing investor QAI Ventures.
The company is focused on developing image analysis technology that leverages computer vision to detect genomic biomarkers and disease signatures from standard blood and cytology smear images. This innovation aims to minimize the reliance on Next-Generation Sequencing, which can be costly and time-consuming in precision oncology workflows.
Moonlight AI's platform transforms routine slide imaging into valuable genomic and diagnostic data using AI models trained on pathology and hematology images. The technology allows laboratories to derive diagnostic insights from existing imaging workflows without the need for additional hardware or manual interventions. A significant portion of the funding will be allocated to expanding the company’s proprietary cytopathology dataset, which integrates whole slide imaging with genomic data across diverse patient populations.
The company is also partnering with an international consortium of clinical partners to create a large-scale cytopathology dataset that combines imaging and genomic data. With plans for team expansion and accelerated commercialization, Moonlight AI aims to advance diagnostic solutions for conditions like myelodysplastic syndrome and non-small cell lung cancer. The transition to a Swiss Stock Corporation marks an important step in its international growth strategy.
This funding round not only highlights Moonlight AI's commitment to improving diagnostic efficiency but also reflects the growing interest in AI applications within healthcare. The potential to enhance laboratory workflows and patient outcomes positions the company as a significant player in the evolving landscape of clinical diagnostics.